Health ❯ Healthcare ❯ Drug Approval
Zepbound Neffy Nasal Spray Approval Imfinzi Approval Inluriyo Teva's Ajovy Epcoritamab Voyxact Approval
Phase 3 data showing a 79% reduction in progression risk underpinned the decision.